S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales

ARCA biopharma (ABIO) Competitors

$1.69
+0.04 (+2.42%)
(As of 02/27/2024 ET)

ABIO vs. OCX, BMRA, TRIB, CDIO, ICCC, AWH, VNRX, TKNO, ACHV, and CALC

Should you be buying ARCA biopharma stock or one of its competitors? The main competitors of ARCA biopharma include OncoCyte (OCX), Biomerica (BMRA), Trinity Biotech (TRIB), Cardio Diagnostics (CDIO), ImmuCell (ICCC), Aspira Women's Health (AWH), VolitionRx (VNRX), Alpha Teknova (TKNO), Achieve Life Sciences (ACHV), and CalciMedica (CALC). These companies are all part of the "medical" sector.

ARCA biopharma vs.

ARCA biopharma (NASDAQ:ABIO) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, community ranking, analyst recommendations, risk and institutional ownership.

In the previous week, ARCA biopharma and ARCA biopharma both had 3 articles in the media. OncoCyte's average media sentiment score of 0.46 beat ARCA biopharma's score of -0.05 indicating that OncoCyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ARCA biopharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
OncoCyte
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

OncoCyte has a consensus target price of $3.87, indicating a potential upside of 30.63%. Given OncoCyte's higher probable upside, analysts clearly believe OncoCyte is more favorable than ARCA biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ARCA biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
OncoCyte
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

ARCA biopharma has higher earnings, but lower revenue than OncoCyte.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARCA biopharmaN/AN/A-$5.34M-$0.37-4.57
OncoCyte$960K25.47-$72.90MN/AN/A

ARCA biopharma has a net margin of 0.00% compared to OncoCyte's net margin of -3,923.58%. ARCA biopharma's return on equity of -13.80% beat OncoCyte's return on equity.

Company Net Margins Return on Equity Return on Assets
ARCA biopharmaN/A -13.80% -13.33%
OncoCyte -3,923.58%-77.26%-33.66%

ARCA biopharma has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, OncoCyte has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.

ARCA biopharma received 120 more outperform votes than OncoCyte when rated by MarketBeat users. Likewise, 43.77% of users gave ARCA biopharma an outperform vote while only 6.38% of users gave OncoCyte an outperform vote.

CompanyUnderperformOutperform
ARCA biopharmaOutperform Votes
123
43.77%
Underperform Votes
158
56.23%
OncoCyteOutperform Votes
3
6.38%
Underperform Votes
44
93.62%

Summary

ARCA biopharma beats OncoCyte on 7 of the 11 factors compared between the two stocks.


Get ARCA biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABIO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABIO vs. The Competition

MetricARCA biopharmaDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$23.93M$2.87B$5.03B$7.49B
Dividend YieldN/A0.82%2.90%3.88%
P/E Ratio-4.5721.16180.9713.65
Price / SalesN/A50.063,099.7964.09
Price / CashN/A5,042.7094.5754.63
Price / Book0.664.224.504.68
Net Income-$5.34M$30.34M$111.98M$210.78M
7 Day Performance3.89%24.03%5.23%2.94%
1 Month Performance0.30%0.94%13.29%5.36%
1 Year Performance-23.18%-27.91%13.34%8.21%

ARCA biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCX
OncoCyte
1.7362 of 5 stars
$2.96
-3.0%
$3.87
+30.6%
-60.2%$24.45M$960,000.000.0075Gap Down
BMRA
Biomerica
0 of 5 stars
$1.25
+3.3%
N/A-53.2%$21.03M$5.34M-3.2962
TRIB
Trinity Biotech
0.0795 of 5 stars
$2.34
+1.7%
N/A-55.4%$17.83M$74.78M-0.62398Analyst Report
Stock Split
Gap Up
CDIO
Cardio Diagnostics
0 of 5 stars
$1.67
-5.6%
N/A+25.1%$34.30MN/A0.007Upcoming Earnings
ICCC
ImmuCell
0 of 5 stars
$5.14
-0.8%
N/A-14.3%$39.84M$18.57M-6.2772News Coverage
Gap Down
AWH
Aspira Women's Health
1.5373 of 5 stars
$4.05
-1.7%
$4.80
+18.5%
-34.1%$41.88M$8.18M-0.3385Gap Up
VNRX
VolitionRx
2.3575 of 5 stars
$0.99
+1.0%
$2.50
+152.4%
N/A$77.93M$310,000.00-1.87114
TKNO
Alpha Teknova
1.1908 of 5 stars
$3.14
-6.8%
N/A-42.0%$92.41M$41.42M-2.29285Gap Down
ACHV
Achieve Life Sciences
1.3469 of 5 stars
$4.50
+10.0%
$19.00
+322.2%
-8.7%$95.27MN/A-2.1420High Trading Volume
CALC
CalciMedica
3.8393 of 5 stars
$4.32
-4.4%
$18.67
+332.1%
N/A$24.56MN/A0.0014Upcoming Earnings

Related Companies and Tools

This page (NASDAQ:ABIO) was last updated on 2/28/2024 by MarketBeat.com Staff